Skip to main content
SpringerLink
Log in

Erythromycin: QT interval prolongation, infantile pyloric stenosis

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Medicines and Healthcare products Regulatory Agency. Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban. Drug Safety Update 14: No. 5, Dec 2020. Available from: URL: https://www.gov.uk/drug-safety-update/erythromycin-caution-required-due-to-cardiac-risks-qt-interval-prolongation-drug-interaction-with-rivaroxaban

  2. Medicines and Healthcare products Regulatory Agency. Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis. Drug Safety Update 14: No. 5, Dec 2020. Available from: URL: https://www.gov.uk/drug-safety-update/erythromycin-update-on-known-risk-of-infantile-hypertrophic-pyloric-stenosis

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erythromycin: QT interval prolongation, infantile pyloric stenosis. Reactions Weekly 1837, 2 (2021). https://doi.org/10.1007/s40278-021-88601-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-88601-6

Search

Navigation